Literature DB >> 25288422

The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies.

Rahul K Nayak1, Steven D Pearson2.   

Abstract

In an effort to control health costs, payers are increasingly turning to step therapy (or "fail first") policies in pharmacy benefit design. These policies restrict coverage of expensive therapies unless patients have already failed treatment with a lower-cost alternative. More than other utilization management tools such as formulary tiering, step therapy raises important ethical concerns regarding the proper balance between cost control and the ability of patients and clinicians to tailor care to the needs of the individual patient. This article provides eight design criteria to guide the ethical development and evaluation of step therapy policies and describes six clinical scenarios in which step therapy may be appropriate. The ethical criteria and scenarios are intended to provide guidance and transparency for insurers, patients, clinicians, and policy makers in choosing and paying for the appropriate therapies. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Access To Care; Ethical Issues; Financing Health Care; Insurance Coverage < Insurance; Pharmaceuticals

Mesh:

Substances:

Year:  2014        PMID: 25288422     DOI: 10.1377/hlthaff.2014.0516

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  8 in total

1.  Step Therapy's Balancing Act - Protecting Patients while Addressing High Drug Prices.

Authors:  Rachel E Sachs; Michael Anne Kyle
Journal:  N Engl J Med       Date:  2022-03-05       Impact factor: 176.079

2.  The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Authors:  Michael E Schatman; Lynn R Webster
Journal:  J Pain Res       Date:  2015-03-18       Impact factor: 3.133

Review 3.  PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.

Authors:  Seth J Baum; Peter P Toth; James A Underberg; Paul Jellinger; Joyce Ross; Katherine Wilemon
Journal:  Clin Cardiol       Date:  2017-03-22       Impact factor: 2.882

4.  Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.

Authors:  Lorraine T Dean; Marshalee George; Kimberley T Lee; Kimlin Ashing
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

5.  Improving quality, affordability, and equity of multiple sclerosis care.

Authors:  Annette Langer-Gould; Shilpa Klocke; Brandon Beaber; Sonu M Brara; Julie Debacker; Oluwasheyi Ayeni; Allen S Nielsen
Journal:  Ann Clin Transl Neurol       Date:  2021-03-10       Impact factor: 4.511

6.  The Multiple Sclerosis Treatment Optimization Program.

Authors:  Annette Langer-Gould; Stephen C Cheng; Bonnie H Li; Michael H Kanter
Journal:  Ann Clin Transl Neurol       Date:  2021-10-18       Impact factor: 4.511

7.  Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.

Authors:  Annette Langer-Gould; Stephen C Cheng; Bonnie H Li; Jessica B Smith; Michael H Kanter
Journal:  Ann Neurol       Date:  2022-03-30       Impact factor: 11.274

8.  Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Authors:  William V Padula; Richard A Larson; Stacie B Dusetzina; Jane F Apperley; Rudiger Hehlmann; Michele Baccarani; Ekkehard Eigendorff; Joelle Guilhot; Francois Guilhot; Rudiger Hehlmann; Francois-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Susanne Saussele; Charles A Schiffer; Richard T Silver; Bengt Simonsson; Rena M Conti
Journal:  J Natl Cancer Inst       Date:  2016-03-04       Impact factor: 13.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.